Full closed loop open‐source algorithm performance comparison in pigs with diabetes

Abstract Understanding how automated insulin delivery (AID) algorithm features impact glucose control under full closed loop delivery represents a critical step toward reducing patient burden by eliminating the need for carbohydrate entries at mealtimes. Here, we use a pig model of diabetes to compare AndroidAPS and Loop open‐source AID systems without meal announcements. Overall time‐in‐range (70–180 mg/dl) for AndroidAPS was 58% ± 5%, while time‐in‐range for Loop was 35% ± 5%. The effect of the algorithms on time‐in‐range differed between meals and overnight. During the overnight monitoring period, pigs had an average time‐in‐range of 90% ± 7% when on AndroidAPS compared to 22% ± 8% on Loop. Time‐in‐hypoglycemia also differed significantly during the lunch meal, whereby pigs running AndroidAPS spent an average of 1.4% (+0.4/−0.8)% in hypoglycemia compared to 10% (+3/−6)% for those using Loop. As algorithm design for closed loop systems continues to develop, the strategies employed in the OpenAPS algorithm (known as oref1) as implemented in AndroidAPS for unannounced meals may result in a better overall control for full closed loop systems.

[1]  J. DeVries,et al.  Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial , 2021, Diabetes Care.

[2]  R. Beck,et al.  A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System , 2020, Diabetes technology & therapeutics.

[3]  Sam W. Baker,et al.  An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients , 2020, Science Translational Medicine.

[4]  R. Paul,et al.  CREATE (Community deRivEd AutomaTEd insulin delivery) trial. Randomised parallel arm open label clinical trial comparing automated insulin delivery using a mobile controller (AnyDANA-loop) with an open-source algorithm with sensor augmented pump therapy in type 1 diabetes , 2020, Journal of Diabetes & Metabolic Disorders.

[5]  Sam W. Baker,et al.  A co-formulation of supramolecularly stabilized insulin and pramlintide enhances meal-time glucagon suppression in diabetic pigs , 2020, Nature Biomedical Engineering.

[6]  R. Langer,et al.  Clinical Opportunities for Continuous Biosensing and Closed-Loop Therapies , 2020 .

[7]  A. Haidar,et al.  A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial , 2020, Diabetes Care.

[8]  Brianna N Gaskill,et al.  Power to the People: Power, Negative Results and Sample Size. , 2019, Journal of the American Association for Laboratory Animal Science : JAALAS.

[9]  FDA authorizes first interoperable, automated insulin dosing controller designed to allow more choices for patients looking to customize their individual diabetes management device system , 2019, Case Medical Research.

[10]  C. Cobelli,et al.  IN SILICO TRIALS OF AN OPEN-SOURCE ANDROID-BASED ARTIFICIAL PANCREAS: A NEW PARADIGM TO TEST SAFETY AND EFFICACY OF DO-IT-YOURSELF SYSTEMS. , 2019, Diabetes technology & therapeutics.

[11]  C. Stettler,et al.  Glycaemic control in individuals with type 1 diabetes using an open source artificial pancreas system (OpenAPS) , 2019, Diabetes, obesity & metabolism.

[12]  E. Atlas,et al.  Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial , 2019, Diabetes Care.

[13]  C. Tan,et al.  A preliminary assessment of vital-signs-integrated patient-assisted intravenous opioid analgesia (VPIA) for postsurgical pain , 2019, BMC Anesthesiology.

[14]  B. Cleal,et al.  Real-World Use of Do-It-Yourself Artificial Pancreas Systems in Children and Adolescents With Type 1 Diabetes: Online Survey and Analysis of Self-Reported Clinical Outcomes , 2019, JMIR mHealth and uHealth.

[15]  F. Doyle,et al.  Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range , 2019, Diabetes Care.

[16]  Z. Šumník,et al.  Excellent Glycemic Control Maintained by Open-Source Hybrid Closed-Loop AndroidAPS During and After Sustained Physical Activity. , 2018, Diabetes technology & therapeutics.

[17]  Dana Lewis,et al.  History and Perspective on DIY Closed Looping , 2018, Journal of diabetes science and technology.

[18]  R. Hovorka,et al.  Is an artificial pancreas (closed‐loop system) for Type 1 diabetes effective? , 2018, Diabetic medicine : a journal of the British Diabetic Association.

[19]  Joshua J. Neumiller,et al.  Medtronic MiniMed 670G Hybrid Closed-Loop System , 2018, Clinical Diabetes.

[20]  Stephen D Patek,et al.  Fully Closed-Loop Multiple Model Probabilistic Predictive Controller Artificial Pancreas Performance in Adolescents and Adults in a Supervised Hotel Setting. , 2018, Diabetes technology & therapeutics.

[21]  R. Rabasa-Lhoret,et al.  The challenges of achieving postprandial glucose control using closed‐loop systems in patients with type 1 diabetes , 2018, Diabetes, obesity & metabolism.

[22]  Dana Lewis,et al.  Real-World Use of Open Source Artificial Pancreas Systems , 2016, Journal of diabetes science and technology.

[23]  M. Jensen-Waern,et al.  Establishment of a Refined Oral Glucose Tolerance Test in Pigs, and Assessment of Insulin, Glucagon and Glucagon-Like Peptide-1 Responses , 2016, PloS one.

[24]  J. Lachin,et al.  Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up , 2016, Diabetes Care.

[25]  M. Phillip,et al.  Closed loop insulin delivery in diabetes. , 2015, Best practice & research. Clinical endocrinology & metabolism.

[26]  Dang Khoa Nguyen,et al.  An Implantable Closedloop Asynchronous Drug Delivery System for the Treatment of Refractory Epilepsy , 2012, IEEE Transactions on Neural Systems and Rehabilitation Engineering.

[27]  David M Maahs,et al.  Epidemiology of type 1 diabetes. , 2010, Endocrinology and metabolism clinics of North America.

[28]  S. Joe Qin,et al.  A survey of industrial model predictive control technology , 2003 .

[29]  A. McElduff,et al.  Diabetes Control and Complications Trial , 1993 .

[30]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[31]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.